Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CD10 established that LL reduces Covid SAEs. Especially with patients in worse shape. And it's well-established that there are no serious side effects to the drug. What possible explanation is there other than that the drug works for Covid?
You don't need to believe Nader, or the other employees/scientists, or the EIND reports, or the papers. You don't need a statistical model, either.
The only logical conclusion is that the drug works, it's just a question of whether it's a home run or a base hit in CD12.
agree completely. setting reasonable expectations is healthy for the market imo
Awesome I'll check in next week!!1!!!111
Sorry just expect more reality based posts from long term posters here. Carry on with the pump
Ya well it's been "next week" for like 6 months. Don't think it serves anyone well to get ppls hopes up
What's the point of posting "could" when they've clearly signaled by their statements and by skipping interim that they want to reach full enrollment? Plus study period, plus time to package the data. Even entertaining the idea of next week is nuts for eua.
EUA next week is not realistic. Cmon
Can't imagine selling based on that call. Shorter term traders probably want to be long for cd12 readout and that's just so close at this point.
Longer term traders are not going to be phased by what has been a routine monthly update. Progress is being made
Question, how is "recoveries" defined here? Is this mortality?
I understand why a large investor should expect a discount, but my point is that it just seems like the company would do the best for the shareholders to raise at a higher valuation post the upcoming trial data. This is an awfully high price to pay for some positive analyst reports, which we could still get on our own anyway with existing investors
so dilute existing shareholders at a poor price to do a bank a favor? and we are ok with that?
why not just wait to raise $ after producing results from the trials? should be easier and less dilutive
weak price action on that news, could be an ugly few weeks
looks like another desperation play
Seems like a lot of money is flowing out of HGEN (-33% on the week) into CYDY (+23% on the week)
changing the primary endpoint and extending the study (and now no interim) does not sound super encouraging
ooof not even the desperation conference call looking like it will help
$1 soon?
It's almost like maybe constant posting with exclamations about "UPLISTING TOMORROW!!!" "$50 SOON!!!!" "LOAD UP HERE!!" mania was a bit unrealistic? idk
Agree that it seems like a good deal for the lender. If CYDY is about to release some awesome data that should put the pps over $10, wouldn't you want to just wait to raise funds til after that?
Can someone post/link to more info about the DSMC "safety peek" that might happen next week?
Is this something we are planning to request and don't know if they'll agree? Or has the DSMC signaled to us that they would/can? Or is it dependent at all on any other conditions (like p2 results)?
My understanding was that the DSMC is always monitoring the data and could intervene at any time. So what's the significance of this potential event?
Thanks
Why does NP feel the need to comment on very short term price action, or feel the need to whine about "bashers" in a paid-for puff piece on Proactive? Act like the CEO of a major company with a good chance to solve major health problems. Keep your focus on the business and producing the results and clean up the sloppily written PRs. And if today's release was going to be limited, that could have been telegraphed on Dr Been or not hinted to at all.
I'm as bullish as anyone on CYDY but these unforced errors are ridiculous and give people like AF ammo.
If CYDY had been silent since the Friday Proactive I think share price would be higher than it is now. Now, in the long run, will it really matter? Probably not, but it doesn't instill a lot of confidence in people.
Why is today the first time we are hearing about a p3 interim at 195 patients?
Perhaps this distribution deal is the finalization of the previously mentioned non-binding agreement?
If so, and if today is the unblinding day for the p2 (which I could be mistaken about) it could be a signal that the distributor saw what they wanted to see.
Thoughts?